Table 3

ORs for breast cancer by quartiles of serum protein measurements for premenopausal women

QuartileQuartile 4 95% CIP for trend
1234
IGF-I (ng/ml)
Median148220278351
Range80–181185–240243–307308–483
Cases/controls13/2016/1719/1418/15
OR, crude1.01.452.091.850.68–5.010.18
OR, adjusteda1.02.03.633.490.65–18.70.051
OR, adjustedb1.01.822.652.010.33–12.40.24
IGFBP-1 (ng/ml)
Median9.724.942.294.9
Range1.2–18.819.2–34.735.8–63.363.8–147.2
Cases/controls18/1512/2118/1518/15
OR, crude1.00.481.01.00.38–2.660.56
OR, adjustedc1.00.532.062.400.61–9.510.18
IGFBP-2 (ng/ml)
Median175269406630
Range67–217218–346349–485494–1236
Cases/controls14/1921/1217/1614/19
OR, crude1.02.381.441.000.37–2.670.54
OR, adjustedc1.02.372.061.100.30–4.070.69
IGFBP-3 (ng/ml)
Median1650212026903190
Range970–18681872–24102440–28802890–4670
Cases/controls13/2016/1817/1520/13
OR, crude1.01.371.742.370.85–6.550.075
OR, adjustedc1.00.412.265.281.13–24.70.033
  • a Adjusted for insulin, glucose, and BMI.

  • b Adjusted for insulin, glucose, BMI, and IGFBP-3.

  • c Adjusted for insulin, glucose, BMI, and IGF-I.